196 related articles for article (PubMed ID: 15774321)
1. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
Valantine H
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
[TBL] [Abstract][Full Text] [Related]
2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
3. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
4. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
[TBL] [Abstract][Full Text] [Related]
5. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
Eisen H
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
[TBL] [Abstract][Full Text] [Related]
6. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
8. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
10. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
[TBL] [Abstract][Full Text] [Related]
11. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
Chou NK; Jan CF; Chi NH; Lee CM; Wu IH; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Chu SH; Wang SS
Transplant Proc; 2012 May; 44(4):897-9. PubMed ID: 22564578
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
13. Everolimus: a review of its use in renal and cardiac transplantation.
Dunn C; Croom KF
Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
Annemans L; Lemkuhl H; Tenderich G; Schulz U; Yang XL; Ricci JF; Hetzer R
Transplant Proc; 2007 Dec; 39(10):3306-12. PubMed ID: 18089377
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in cardiac-transplant recipients.
Banas B; Böger C; Krämer B
N Engl J Med; 2003 Dec; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
[No Abstract] [Full Text] [Related]
17. Proliferation signal inhibitors in cardiac transplantation.
Gustafsson F; Ross HJ
Curr Opin Cardiol; 2007 Mar; 22(2):111-6. PubMed ID: 17284989
[TBL] [Abstract][Full Text] [Related]
18. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
[TBL] [Abstract][Full Text] [Related]
19. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments.
Neumayer HH
Transplantation; 2005 May; 79(9 Suppl):S72-5. PubMed ID: 15880019
[TBL] [Abstract][Full Text] [Related]
20. Vascular remodeling 1 year after cardiac transplantation.
Li H; Tanaka K; Chhabra A; Oeser B; Kobashigawa JA; Tobis JM
J Heart Lung Transplant; 2007 Jan; 26(1):56-62. PubMed ID: 17234518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
